Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Securities Limited submitted its Q3 FY26 and 9M FY26 results on February 12, 2026, reviewed by new auditor Goyal Nagpal & Co. On a standalone basis, total revenue fell sharply to Rs 101.25 lakhs in Q3 (vs Rs 334.90 lakhs in Q3 FY25, a ~70% drop) and to Rs 315.47 lakhs for 9M FY26 (vs Rs 776.05 lakhs). Standalone profit after tax also declined to Rs 37.88 lakhs in Q3 (vs Rs 71.37 lakhs) and Rs 42.82 lakhs for 9M (vs Rs 124.13 lakhs). On a consolidated basis, results look much stronger thanks to share of profits from associates Titan Biotech and Peptech Biosciences. Consolidated profit after tax rose to Rs 367.18 lakhs in Q3 (vs Rs 254.34 lakhs, ~44% growth) and Rs 966.31 lakhs for 9M (vs Rs 906.15 lakhs). Consolidated EPS for 9M stood at Rs 3.86 vs Rs 3.62.
The standalone business is clearly shrinking, but the stock's value to shareholders now depends heavily on the performance of its associate companies (Titan Biotech and Peptech Biosciences), whose profits drove the consolidated bottom line higher. The change of auditor between Q2 and Q3 FY26 is a notable governance point investors should monitor.